Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma
- 43 Downloads
To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences.
Materials and methods
GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations in grade and stage at recurrence and modifications in GP-170 expression were also studied.
No significant correlation between GP-170 expression and G-grade and T-category was found. A significant correlation was detected between GP-170 expression and recurrence (P=0.0383). It showed a biphasic pattern, i.e., tumors that did not express GP-170 had a higher recurrence rate, but high GP-170 levels were also associated with an increasing risk of recurrence. Intravesical chemotherapy did not induce significative variations in GP-170 expression. No correlation was found between progression and GP-170.
GP-170 seems to be an independent prognostic factor for recurrence in superficial bladder tumors. A negative GP-170 pattern and high levels of GP-170 are associated with an increasing risk of recurrence but have no impact upon progression. In our experience, GP-170 is neither induced nor modified by intravesical chemotherapy, although it might represent a factor of chemoresistance when strongly expressed.
KeywordsSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapy
The study was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and from a grant (No R1D470PQ52001) from the Ministero Italiano dell' Istruzione, Università e Ricerca (MIUR). Statistical analysis was conducted by Rosalinda Allegro.
- Kim WJ, Kakehi Y, Yoshida O (1997) Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells. Int J Urol 4:583–590PubMedGoogle Scholar
- Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, et al (1995) Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 11:1301–1310Google Scholar
- Toth K, Vaughan MM, Slocum HK, Arredondo MA, Takida H, Baker RM, Rustum YM (1993) New immunohistochemical "sandwich" staining method for mdr-1 p-glycoprotein detection with JSB-1 monoclonal antibody in formalin fixed, paraffin-embedded human tissues. Proc Am Assoc Cancer Res 34:312Google Scholar